Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (Becton, Dickinson and Company) (NYSE: BDX) has launched the BD FACSDiscover™ S8 Cell Sorter featuring revolutionary BD CellView™ Image Technology at the ISAC CYTO 2022 conference. This new technology allows researchers to sort and view cells rapidly and accurately, enhancing research in virology, oncology, and other fields. The sorter combines spectral flow cytometry with detailed image analysis, enabling previously unidentifiable cell sorting. This development aims to redefine standards in cell sorting, potentially accelerating medical discoveries and therapeutic advancements.
BD (Becton, Dickinson and Company) announced its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at 11:00 a.m. Eastern Time. The live webcast will be accessible via the BD investor relations website, with a replay available post-event. As a leading global medical technology company, BD focuses on improving medical discovery and care delivery, supported by a dedicated workforce of 75,000 employees worldwide.
BD has received 510(k) clearance from the FDA for its BD COR™ MX instrument, enhancing STI diagnostics capabilities. The first assay available detects Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. This system automates laboratory workflows, enabling the processing of 1,700 specimens and delivering up to 1,000 results in 24 hours. By reducing manual interactions, it aims to alleviate staff workloads, especially critical amidst ongoing healthcare staffing challenges. Future assays for women's health and other indications are in development.
Babson Diagnostics and BD (Becton, Dickinson and Company) have expanded their partnership to enhance blood sample collection, making it more patient-centered and less invasive. Announced on May 11, 2022, the collaboration aims to enable at-home blood sample collection and broaden test capabilities to include pediatric diagnostics. This initiative, developed since 2019, leverages advanced capillary collection technology, requiring only a fraction of the blood volume compared to traditional methods. The companies aim to improve patient compliance by providing a more convenient testing experience.
BD (Becton, Dickinson and Company) reported a revenue increase of 2.1% to $5.0 billion for Q2 FY2022, aided by a base revenue growth of 8.2%. However, COVID-only testing revenues fell to $214 million from $474 million. GAAP diluted EPS rose 59.6% to $1.50, while adjusted EPS was slightly down at $3.18. The company updated its fiscal 2022 guidance, projecting revenues between $19.6 and $19.8 billion, and adjusted EPS between $12.85 and $13.00. This reflects an increase in base business currency-neutral revenue growth estimates to 6.75%-7.75% and an anticipated headwind from foreign exchange.
BD (Becton, Dickinson and Company) has introduced its Scientific Advisory Board (SAB), comprising leading experts in health care, science, and technology. The board will provide insights on BD's innovation pipeline, technology capabilities, and emerging trends in the medical field. CEO Tom Polen stated that the SAB aims to enhance patient outcomes and drive growth through impactful innovations. Notable members include John DeFord from Purdue University and Claire Fraser from the University of Maryland. This strategic move is part of BD's commitment to lead in advancing health care technologies.
BD (Becton, Dickinson and Company) will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 12:00 p.m. Pacific Time. Investors can access the live webcast from BD's investor relations website, with a replay available post-event. BD, a leading global medical technology firm, is dedicated to advancing health through innovative technology and solutions, supporting healthcare providers and improving patient outcomes. BD boasts a workforce of 75,000 and operates globally to address significant health challenges.
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, set to be paid on June 30, 2022. Shareholders on record by June 9, 2022 will receive this payment, resulting in an annual dividend rate of $3.48 per share. This decision reflects the company's commitment to return value to its shareholders while maintaining a strong presence in global medical technology.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced the launch of BD Horizon RealYellow™ 586 Reagents, a breakthrough in flow cytometry developed using novel dye technology and AI guidance. These reagents enable improved data resolution, facilitating deeper biological insights in oncology, autoimmune disorders, and infectious diseases. The reagents support both conventional and spectral flow cytometry, allowing researchers to analyze more markers per sample. With their global availability, BD aims to enhance research capabilities and accelerate drug development.
BD (Becton, Dickinson and Company) has established the Sustainable Medical Technology Institute to enhance its environmental sustainability efforts. This initiative targets three key areas: sustainable product design, sterilization technologies, and materials of concern. By leveraging interdisciplinary expertise, BD aims to reduce the environmental impact of its products while supporting its 2030+ environmental, social, and governance (ESG) commitments. The institute will collaborate globally and set environmental criteria for new products to better meet sustainability needs.